Drug survival rates for tumour necrosis factor-α antagonists in psoriasis

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) M. M. Soliman et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study

(2010) R.T. Woolf et al.   BRITISH JOURNAL OF DERMATOLOGY

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register

(2010) S. M. M. Verstappen et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

(2009) Amr A Saad et al.   ARTHRITIS RESEARCH & THERAPY